Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis



Status:Completed
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:November 2011
End Date:March 2013

Use our guide to learn which trials are right for you!

An Open-label Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg Administered Subcutaneously in Subjects With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

The primary objective was to evaluate the incidence of clinically significant hypocalcemia
following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic
kidney disease (CKD) and CKD on dialysis


Inclusion Criteria:

- Subjects at least 18 years old with severe CKD (defined as creatinine clearance < 30
mL/min at both screening assessments) and CKD requiring hemodialysis

- Additional inclusion criteria apply

Exclusion Criteria:

- Subjects must have calcium, phosphate, and magnesium levels appropriate for their
condition and must not have other uncontrolled co-morbidities.

- Additional exclusion criteria apply
We found this trial at
7
sites
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Meridian, ID
Click here to add this to my saved trials
?
mi
from
Orangeburg, SC
Click here to add this to my saved trials
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Tempe, AZ
Click here to add this to my saved trials